Global Generic Central Nervous System Drugs Market Projected to Grow at 7.4% CAGR, Reaching $125.42 Billion by 2029

Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.

Generic Central Nervous System Drugs Market Size Valuation Forecast: What Will the Market Be Worth by 2025?
The size of the generic central nervous system drugs market has seen significant expansion recently. Projected growth figures show an increase from $88.43 billion in 2024 to $94.38 billion in 2025, with a compound annual growth rate (CAGR) predicted at 6.7%. Factors contributing to the growth experienced in the historical period include the rising number of surgeries, robust growth in emerging markets, increase in drug research and development, aging population, and amplified healthcare spending.

Generic Central Nervous System Drugs Market Size Forecast: What's the Projected Valuation by 2029?
The market size for generic central nervous system drugs is projected to experience substantial growth in the coming years, increasing to $125.42 billion by 2029, with a compound annual growth rate (CAGR) of 7.4%. The anticipated growth during this forecast period can be credited to several reasons such as increased mental health awareness initiatives from government bodies, heightened expenditure on healthcare, an uptick in the elderly population, and a robust pipeline for drugs. The main developments in the forecast period encompass investments in wearable technology, the use of biomarkers in CNS development, alterations to existing drugs, investments in the drug pipeline, the application of 3D printing for drug production, and emphasis on forming partnerships with research institutions and large corporations.

View the full report here:
https://www.thebusinessresearchcompany.com/report/generic-central-nervous-system-drugs-global-market-report

What Are the Drivers Transforming the Generic Central Nervous System Drugs Market?
The expected surge in the generic central nervous system (CNS) drug market can be attributed to the rising prevalence of mental health disorders. Such disorders significantly affect a person's emotional stability, cognitive performance, or behaviour, often causing distress or functional difficulties in significant areas. Generic CNS drugs have become paramount in treating mental health disorders as they provide cost-effective and easily accessible alternatives. The Health and Social Care Information Centre, a UK-based governmental organization providing services to professionals, doctors, and administrators in health and social care, reported a rise in mental disorder cases among 17- to 19-year-olds. The rate increased from 17.4% in 2021 to 25.7% in 2022. Thus, the escalation in mental health disorders contributes to the growth of the generic central nervous system (CNS) drug market.

Get your free sample here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=9315&type=smp

What Long-Term Trends Will Define the Future of the Generic Central Nervous System Drugs Market?
Top firms in the generic central nervous system drugs market are putting their efforts into creating biosimilars for central nervous system (CNS) diseases. The trend is growing for the creation and authorization of biosimilars for specific biologic drugs applied in CNS disorders, providing more affordable options in comparison to branded biologics. For example, natalizumab-sztn, the first-ever biosimilar to treat recurring forms of multiple sclerosis (MS), was launched by Sandoz, a pharmaceutical company based in Switzerland, in October 2023. This encompasses clinically isolated syndrome, relapsing-remitting MS, and active secondary progressive MS. MS is a chronic, progressive autoimmune disease that influences the central nervous system. Most individuals affected by the disease experience phases of remission and relapse, adversely affecting their life quality. However, the treatment is not recommended for patients suffering from progressive multifocal leukoencephalopathy (PML) or those who have had PML previously.

Which Segments in the Generic Central Nervous System Drugs Market Offer the Most Profit Potential?
The generic central nervous system drugs market covered in this report is segmented -

1) By Type: Multiple Sclerosis (MS), Anti-Psychotic, Analgesics, Anti-Parkinson Drugs, Anesthetics, Anti-Epileptics, Anti-Depressants, Other Types
2) By Drug Classification: Branded Drugs, Generic Drugs
3) By Disease: Neurovascular Diseases, CNS Trauma, Mental Health, Neurodegenerative Diseases, Infectious Diseases, CNS Cancer
4) By Route Of Administration: Oral, Intravenous, Intranasal Or Inhalation, Other Route Of Administrations
5) By Mode Of Purchase: Over-The-counter drugs, Prescription-Based Drugs
6) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Other Distribution Channels

Subsegments:
1) By Multiple Sclerosis (MS): Interferons, Glatiramer Acetate, Sphingosine-1 Phosphate Receptor Modulators, Monoclonal Antibodies
2) By Anti-Psychotic: Atypical Antipsychotics, Typical Antipsychotics
3) By Analgesics: Non-Opioid Analgesics, Opioid Analgesics, Combination Analgesics
4) By Anti-Parkinson Drugs: Dopamine Agonists, MAO-B Inhibitors, COMT Inhibitors, Anticholinergics
5) By Anesthetics: General Anesthetics, Local Anesthetics
6) By Anti-Epileptics: Sodium Channel Blockers, GABA Enhancers, Glutamate Modulators, Other Mechanisms
7) By Anti-Depressants: Selective Serotonin Reuptake Inhibitors (SSRIs), Serotonin-Norepinephrine Reuptake Inhibitors (SNRIs), Tricyclic Antidepressants (TCAs), Monoamine Oxidase Inhibitors (MAOIs), Atypical Antidepressants
8) By Other Types: Cognitive Enhancers, Anxiolytics, Sleep Aids

Tailor your insights and customize the full report here:
https://www.thebusinessresearchcompany.com/customise?id=9315&type=smp

Which Firms Dominate the Generic Central Nervous System Drugs Market by Market Share and Revenue in 2025?
Major companies operating in the generic central nervous system drugs market include Biogen Inc., Johnson & Johnson, Hoffmann-La Roche Ltd, Novartis AG, UCB, Sanofi, Pfizer Inc., Merck KGaA, Sumitomo Dainippon Pharma, AbbVie, Recipharm AB, Neuraxpharm, Sun Pharmaceutical limited, Ranbaxy Laboratories, Merz Pharma GmbH & Co. KGaAare, AstraZeneca, Apotex, Gilead Sciences, Bayer, GlaxoSmithKline, Amgen, Abbott Laboratories, Janssen Pharmaceutica, Teva Canada, Accord Healthcare Inc., Acerus Pharmaceuticals Corporation, Amgen, EMS Pharma, Hypermarcas, Eurofarma, Teuto Brasileiro, Biolab Farmaceutica, Cristalia, União Quimica, Boehringer Ingelheim, Eli Lilly and Company, Adcock Ingram

Which Regions Offer the Highest Growth Potential in the Generic Central Nervous System Drugs Market?
North America was the largest region in the generic central nervous system drugs market in 2024. The regions covered in the generic central nervous system drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Purchase the full report today:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=9315

This Report Supports:
1. Business Leaders & Investors - To identify growth opportunities, assess risks, and guide strategic decisions.
2. Manufacturers & Suppliers - To understand market trends, customer demand, and competitive positioning.
3. Policy Makers & Regulators - To track industry developments and align regulatory frameworks.
4. Consultants & Analysts - To support market entry, expansion strategies, and client advisory work.

Connect with us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ.

Contact Us
Europe: +44 7882 955267,
Asia: +91 88972 63534,
Americas - +1 310-496-7795 or
Email: mailto:info@tbrc.info

Learn More About The Business Research Company
With over 15,000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Our flagship product, the Global Market Model delivers comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.